PMV PHARMACEUTICALS, INC. Operating Cash Flow
PMV PHARMACEUTICALS, INC. (PMVP) reported Operating Cash Flow of -$34.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$14.58M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$19.68M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$17.19M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$19.82M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$73.58M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$51.28M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$55.66M.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$63.76M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$34.26M 10-Q · filed 2026-08-14 | -$51.45M derived: sum of 3 quarters · filed 2026-08-14 | -$71.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$19.68M 10-Q · filed 2026-05-12 | -$36.87M derived: sum of 2 quarters · filed 2026-05-12 | -$56.69M derived: sum of 3 quarters · filed 2026-05-12 | -$74.99M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$17.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$37.01M derived: sum of 2 quarters · filed 2026-03-06 | -$55.31M derived: sum of 3 quarters · filed 2026-08-14 | -$73.58M 10-K · filed 2026-03-06 |
| 2025-09-30 | -$19.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$38.12M derived: sum of 2 quarters · filed 2026-08-14 | -$56.39M 10-Q · filed 2025-11-12 | -$73.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$18.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$36.57M 10-Q · filed 2026-08-14 | -$53.23M derived: sum of 3 quarters · filed 2026-08-14 | -$70.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$18.27M 10-Q · filed 2026-05-12 | -$34.93M derived: sum of 2 quarters · filed 2026-05-12 | -$51.77M derived: sum of 3 quarters · filed 2026-05-12 | -$53.36M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$16.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$33.50M derived: sum of 2 quarters · filed 2026-03-06 | -$35.10M derived: sum of 3 quarters · filed 2026-03-06 | -$51.28M 10-K · filed 2026-03-06 |
| 2024-09-30 | -$16.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$18.44M derived: sum of 2 quarters · filed 2025-11-12 | -$34.62M 10-Q · filed 2025-11-12 | -$46.71M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$17.78M 10-Q · filed 2025-08-07 | -$29.87M derived: sum of 3 quarters · filed 2026-03-06 | -$45.53M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | -$16.18M 10-Q · filed 2025-05-09 | -$28.27M derived: sum of 2 quarters · filed 2026-03-06 | -$43.93M derived: sum of 3 quarters · filed 2026-03-06 | -$56.83M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | -$12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$27.74M derived: sum of 2 quarters · filed 2026-03-06 | -$40.65M derived: sum of 3 quarters · filed 2026-03-06 | -$55.66M 10-K · filed 2026-03-06 |
| 2023-09-30 | -$15.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$28.56M derived: sum of 2 quarters · filed 2024-11-07 | -$43.57M 10-Q · filed 2024-11-07 | -$58.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$27.91M 10-Q · filed 2024-08-08 | -$43.24M derived: sum of 3 quarters · filed 2025-03-03 | -$60.00M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$15.01M 10-Q · filed 2024-05-09 | -$30.34M derived: sum of 2 quarters · filed 2025-03-03 | -$47.09M derived: sum of 3 quarters · filed 2025-03-03 | -$60.77M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$15.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$32.08M derived: sum of 2 quarters · filed 2025-03-03 | -$45.76M derived: sum of 3 quarters · filed 2025-03-03 | -$63.76M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$16.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$30.44M derived: sum of 2 quarters · filed 2023-11-09 | -$48.44M 10-Q · filed 2023-11-09 | -$60.46M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$13.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$31.68M 10-Q · filed 2023-08-09 | -$43.70M derived: sum of 3 quarters · filed 2024-02-29 | -$56.10M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$18.00M 10-Q · filed 2023-05-10 | -$30.03M derived: sum of 2 quarters · filed 2024-02-29 | -$42.42M derived: sum of 3 quarters · filed 2024-02-29 | -$51.66M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$12.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$24.43M derived: sum of 2 quarters · filed 2024-02-29 | -$33.67M derived: sum of 3 quarters · filed 2024-02-29 | -$46.57M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$12.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$21.64M derived: sum of 2 quarters · filed 2022-11-08 | -$34.54M 10-Q · filed 2022-11-08 | -$44.85M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$9.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$22.14M 10-Q · filed 2022-08-09 | -$32.46M derived: sum of 3 quarters · filed 2023-03-01 | -$39.85M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$12.90M 10-Q · filed 2022-05-10 | -$23.22M derived: sum of 2 quarters · filed 2023-03-01 | -$30.61M derived: sum of 3 quarters · filed 2023-03-01 | -$37.51M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$10.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$17.70M derived: sum of 2 quarters · filed 2023-03-01 | -$24.60M derived: sum of 3 quarters · filed 2023-03-01 | -$32.74M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$7.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$14.29M derived: sum of 2 quarters · filed 2021-11-12 | -$22.43M 10-Q · filed 2021-11-12 | -$27.55M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$6.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$15.03M 10-Q · filed 2021-08-13 | -$20.16M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2020-03-31 | -$8.14M 10-Q · filed 2021-05-14 | -$13.27M derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2019-12-31 | -$5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$22.07M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$16.94M 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | -$15.18M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |